June 13, 2019

To
The Secretary
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code - 532523

To
The Secretary
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol- BIOCON

Dear Sir/Madam,

Sub: Investor Presentation on “Biosimilars- The Next Big Global Healthcare Opportunity”.
Ref: Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

With reference to the captioned subject, please find enclosed Investor Presentation.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For BIOCON LIMITED

[Signature]
Dr. Arun S Chandavarkar
CEO & Joint Managing Director
DIN: 01596180

Encl: Investor Presentation
Biocon Biologics
A Global Biosimilar Player
Ahead of the curve

Dr. Christiane Hamacher, CEO - Biocon Biologics
13 June 2019
Biosimilars – The Next Big Global Healthcare Opportunity

High investments, quality focus and scale needed to deliver biosimilars across the world

A Biosimilar Is A Biological Product

- Large and generally complex molecules
- Produced from living organisms
- Carefully monitored to ensure consistent quality

A Biosimilar Has No Clinically Meaningful Differences From A Reference Product

- Pharmacokinetic and, if needed, pharmacodynamic studies
- Immunogenicity assessment
- Additional clinical studies as needed

A Biosimilar Is Highly Similar To A Reference Product

- Purity
- Molecular structure
- Bioactivity

The data from these comparisons must show that the biosimilar is highly similar to the reference product.

A Biosimilar Is Approved By FDA After Rigorous Evaluation And Testing By The Applicant

- Meet FDA's rigorous standards for approval
- Are manufactured in FDA-licensed facilities
- Are tracked as part of post-market surveillance to ensure continued safety

Source: US FDA; https://www.fda.gov/media/108905/download
Biosimilars – The Next Big Global Healthcare Opportunity
To deliver affordable innovation globally

- For the treatment of severe diseases
- Key to progress towards universal healthcare
- To significantly lessen the financial burden of healthcare systems#
- An attractive business opportunity
  - 11 of the 15 Top Selling Drugs in the World are Biologics*
  - $120 Bn in revenue 2018*

* IMS Health – Impact of Biosimilar Competition June 2016
Biocon Biologics - Fully Integrated Player For Biosimilars
Getting it right the first time – an early mover

1. One of the broadest pipelines
2. Many firsts to our credit
3. Products commercialized in U.S., Europe, Japan and Most of the World
4. Cost competitive
5. Global scale manufacturing capability
6. Marquee partnerships
7. Innovation in various parts of the value chain
Biocon Biologics - Leveraging Global Trends In Healthcare
Bringing innovation to healthcare

**Patient-centricity**
1. Funding & payment models
2. Patient ecosystems
3. Policy work

**Digital disruption**
1. Drug development and manufacturing
2. Digital marketing and distribution
Biocon Biologics – Business Performance in FY19
A landmark year – strong realization in developed and Most of the World markets

- Crossed USD 200 million revenue milestone
- Revenue growth of 97% YoY
- 27% of consolidated Biocon revenue FY19 vs 17% last year
- Profit Before Interest and Tax (PBIT) margin rose to 26% in FY19 vs -2% FY18
- High quality affordable innovation delivered to ~ 2 mio patients
Biocon Biologics - What to Expect In The Next Decade?
Building on the current momentum

- Accelerating the growth path
- Ability to further differentiate and disrupt healthcare
- Further strengthening the broad pipeline
- Leveraging our affordable innovation model & global scale R&D

Only few players might be able to succeed in the Biosimilar market

BIOCON ADVANTAGE
- Competitive Cost
- Fully integrated from Lab to market
- Capacity enhancement aligned with expanding global demand
- Next wave of biosimilars through direct commercialization
- Investing in digital marketing and new technologies across the value chain
Biocon Biologics - Set For Success - A Major Global Player in Biosimilars
A fully integrated player who gets its right the first time

1. Well positioned to further build on our early mover advantage
2. Continued investments in R&D and capacity to build on the early success story
3. Able to innovate to accelerate growth
   • digital disruption
   • patient-centricity